respiratory
Pulmonary fibrosis

IPF diagnosis and management starting to move forward


The relative excitement of having medications to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF) is offset by the reality that they only help some patients. According to a summary of the evidence, anti-fibrotic medications have a clinically meaningful impact in mild to moderate IPF but there is little data to guide treatment ...

Already a member?

Enter your email to keep reading.


OR